Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Jones Mitchell Lawrence | CEO, CFO, Director | May 06 '24 | Option Exercise | 0.00 | 460 | 0 | 880 | May 08 06:37 PM | Finley John David | CEO, CFO, Director | May 06 '24 | Option Exercise | 0.00 | 443 | 0 | 6,832 | May 08 06:36 PM | Finley John David | CEO, CFO, Director | Mar 11 '24 | Option Exercise | 0.00 | 5,558 | 0 | 96,849 | Mar 12 06:29 PM | Neal James R | Director | Feb 09 '24 | Option Exercise | 0.00 | 10,920 | 0 | 10,920 | Feb 13 03:08 PM | Trenschel Robert J. | Director | Feb 08 '24 | Option Exercise | 0.00 | 10,920 | 0 | 10,920 | Feb 13 03:08 PM | Csimma Cristina | Director | Feb 08 '24 | Option Exercise | 0.00 | 12,800 | 0 | 12,862 | Feb 13 03:08 PM | Diaz Stephanie | Director | Feb 08 '24 | Option Exercise | 0.00 | 12,800 | 0 | 12,800 | Feb 13 03:08 PM | Finley John David | CEO, CFO, Director | Feb 06 '24 | Option Exercise | 0.00 | 6,642 | 0 | 91,291 | Feb 08 04:37 PM | Jones Mitchell Lawrence | Chief Medical Officer | Feb 06 '24 | Option Exercise | 0.00 | 6,891 | 0 | 9,815 | Feb 08 04:38 PM | Finley John David | CEO, CFO, Director | Feb 06 '24 | Buy | 0.47 | 10,000 | 4,692 | 84,649 | Feb 07 08:30 AM | Williams Donald Allen | Director | Jan 31 '24 | Buy | 0.60 | 10,000 | 6,050 | 30,000 | Feb 01 08:30 AM | Finley John David | CEO, CFO, Director | Jan 31 '24 | Buy | 0.56 | 10,000 | 5,590 | 74,649 | Feb 01 08:30 AM | Finley John David | CEO, CFO, Director | Jan 03 '24 | Option Exercise | 0.00 | 1,309 | 0 | 64,649 | Jan 05 04:00 PM | Finley John David | CEO, CFO, Director | Dec 11 '23 | Option Exercise | 0.00 | 5,559 | 0 | 63,340 | Dec 19 05:57 PM | Finley John David | CEO, CFO, Director | Nov 06 '23 | Option Exercise | 0.00 | 3,475 | 0 | 47,781 | Nov 08 05:01 PM | Jones Mitchell Lawrence | Chief Medical Officer | Nov 06 '23 | Option Exercise | 0.00 | 4,556 | 0 | 4,556 | Nov 08 05:01 PM | Finley John David | CEO, CFO, Director | Oct 03 '23 | Option Exercise | 0.00 | 1,309 | 0 | 44,703 | Oct 05 05:46 PM | Williams Donald Allen | Director | Sep 27 '23 | Buy | 0.54 | 20,000 | 10,800 | 20,000 | Sep 29 09:25 AM | Finley John David | CEO, CFO, Director | Sep 27 '23 | Buy | 0.54 | 15,000 | 8,088 | 43,394 | Sep 29 09:21 AM | Trenschel Robert J. | Director | Sep 14 '23 | Sale | 0.64 | 300 | 192 | 0 | Sep 15 05:15 PM | Finley John David | CEO, CFO, Director | Sep 13 '23 | Buy | 0.66 | 15,000 | 9,825 | 28,394 | Sep 14 05:00 PM | Finley John David | CEO, CFO, Director | Sep 11 '23 | Option Exercise | 0.00 | 5,558 | 0 | 15,186 | Sep 13 04:55 PM | Finley John David | CEO, CFO, Director | Aug 06 '23 | Option Exercise | 0.00 | 3,475 | 0 | 11,057 | Aug 14 06:33 PM | Finley John David | CEO, CFO, Director | Jul 03 '23 | Option Exercise | 0.00 | 1,309 | 0 | 7,582 | Jul 06 06:27 PM | Finley John David | CEO, CFO, Director | Jun 12 '23 | Option Exercise | 0.00 | 3,475 | 0 | 7,323 | Jun 14 06:23 PM |
|